Skip to main content
Clinical Trials/DRKS00034370
DRKS00034370
Not yet recruiting
Phase 2

A randomized clinical feasibility trial of time-restricted eating to improve response to therapy of multiple myeloma - FASTINA

KSH Campus Lübeck, Klinik für Hämatologie und Onkologie0 sites54 target enrollmentJune 21, 2024

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
C90.0
Sponsor
KSH Campus Lübeck, Klinik für Hämatologie und Onkologie
Enrollment
54
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 21, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
KSH Campus Lübeck, Klinik für Hämatologie und Onkologie

Eligibility Criteria

Inclusion Criteria

  • 1\.Newly diagnosed or relapsed/ refractory according to IMWG criteria
  • 2\.Willingness to receive system therapy (after detailed explanation)
  • 3\.Ability to understand and willingness to sign written informed consent.
  • 4\.Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures
  • 5\.Signed informed consent must be obtained before any study specific procedure
  • 6\.Ability to complete questionnaires individually
  • 7\.Willingness and ability to follow time\-restricted eating when randomized in experimental Arm A
  • 8\.WHO performance status 0\-2 (WHO\=3 is allowed only if caused by multiple myeloma and not by co\-morbid conditions)
  • 9\.For Women of Childbearing potential and Males with female partners of childbearing potential: Willingness to use adequate contraception

Exclusion Criteria

  • 1\.Inability to undergo caloric restriction, BMI \< 20 kg/m² or cachexia (defined as unintentional weight loss in the last 6 months of more than 5% or unintentional weight loss in the last 12 months of more than 10%)
  • 2\.Recent autologous stem cell transplantation (less than 100 days ago)
  • 3\.History of eating disorder
  • 4\.Ongoing nutritional support in the form of high\-calorie drinks or parenteral nutrition
  • 5\.Active infection requiring intravenous broad spectrum antibiotica, antifungal medication or antiviral treatment at time point of inclusion.
  • 6\.Uncontrolled Diabetes mellitus requiring treatment.
  • 7\.Any condition requiring continuous food supplement.
  • 8\.Severe grade 3 thyroid dysfunction
  • 9\.Known to be HIV\+ or to have hepatitis A, B, or C active infection
  • 10\.Uncontrolled or active HBV infection: Patients with positive HBsAg and/or HBV DNA.

Outcomes

Primary Outcomes

Not specified

Similar Trials